Floatz logo

Pembrolizumab

Stage III Bladder Cancer AJCC v8

Fred Hutchinson Cancer Centermonoclonal_antibodyPhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Stage III Bladder Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 2BB
Atezolizumab
National Cancer Institute (NCI)
Phase 2BB
TRASTUZUMAB
Iambic Therapeutics, Inc
Phase 2BB
Carboplatin
Iambic Therapeutics, Inc
Phase 2BB
Nivolumab
M.D. Anderson Cancer Center
Phase 2B

View all 45 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →